Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts)

I Pires da Silva; Serigne Lo; Matteo S. Carlino; Richard A Scolyer; Alexander M. Menzies; Georgina V. Long

doi:10.1093/annonc/mdz255.016

Related publications

Article2019

Circulating tumor DNA (ctDNA) in metastatic melanoma (MM) patients (pts) with brain metastases (mets).

Jenny Lee, Alexander M. Menzies, Matteo S. Carlino, Richard Kefford, Richard A Scolyer, Georgina V. Long, Helen Rizos

Article2021

Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).

Georgina V. Long, Victoria Atkinson, Serigne Lo, Alexander Guminski, Shahneen Sandhu, Michael P. Brown, Maria Gonzalez, Richard A. Scolyer, Louise Emmett, Grant A. McArthur, Alexander M. Menzies

Article2023

Impact of risk factors on overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS).

Masatoshi Kudo, Richard S. Finn, Tim Meyer, Frédéric Boisserie, Songzi Li, Yaxi Chen, Ramil Abdrashitov, Andrew X. Zhu, Arndt Vogel, Shukui Qin

Article2012

Clinical and Pathologic Factors Associated with Distant Metastasis and Survival in Patients with Thin Primary Cutaneous Melanoma

Rajmohan Murali, Lauren E. Haydu, Georgina V. Long, Michael J. Quinn, Robyn P.M. Saw, Kerwin F. Shannon, Andrew J. Spillane, Jonathan R. Stretch, Richard Kefford, John F. Thompson, Richard A Scolyer

Article2017

A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC).

Georgina V. Long, Victoria Atkinson, Alexander M. Menzies, Serigne Lo, Alexander Guminski, Michael P. Brown, M. M. González, Katrina Diamante, Shahneen Sandhu, Richard A. Scolyer, Louise Emmett, Grant A. McArthur